Latest Investor Confidence News

Terramin Australia’s attempt to secure a mining lease for its Bird in Hand Gold Project has been rejected by the South Australian Supreme Court, which upheld the government’s refusal and reservation of the land. The company is set to appeal, keeping the project’s future uncertain.

Activeport has successfully closed a $6.1 million capital raise, including a significant placement to new institutional investor MWP Partners, positioning the company for accelerated growth in the global telecommunications and data centre software markets.

Nimy Resources has addressed an ASX inquiry regarding recent spikes in its share price and trading volume, confirming no undisclosed information but highlighting ongoing work on its maiden JORC Exploration Target for gallium.

Magellan Asset Management has announced target cash distributions for its suite of funds for the six months ending June 2025, signaling steady income expectations for investors.

North Stawell Minerals has launched its 2025 diamond drilling program targeting significant gold mineralisation at the Wildwood and Darlington prospects in Victoria, backed by a recent $1.3 million capital raise.

Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.

Resources & Energy Group Ltd (REZ) has clarified recent trading activity in its shares, attributing the surge to a significant rise in gold prices rather than undisclosed information. The company remains focused on its Maranoa gold recovery program, with further results pending.

HITIQ Limited has received $1.6 million from the R&D Tax Incentive Scheme, using most of it to repay its RDTI Facility with Keystone Capital Partners, signaling a strategic move to streamline its R&D funding.

First Graphene Limited has responded to an ASX price query, attributing its recent share price and volume surge to increased buying activity in Germany linked to prior commercial announcements, while reaffirming full compliance with ASX disclosure rules.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.

Latrobe Magnesium Limited has responded to an ASX price query, denying any undisclosed information that could explain the recent sharp drop in its share price and surge in trading volume.

The Australian Takeovers Panel has declared unacceptable circumstances in Alara Resources Limited's recent rights issue, citing inadequate disclosure and potential control issues involving Al Tasnim Infrastructure LLC. The company faces a costs order and must reassess its fundraising approach.